Related Experiment Video
Updated: Jun 6, 2026

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
Published on: February 9, 2024
Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through
Wen-Yu Huang1, Pei-Ming Yang, Yu-Fan Chang
1Department of Pharmacology, College of Medicine, National Taiwan University, Taipei 10018, Taiwan.
Abstract:
Methotrexate (MTX) is a dihydrofolate reductase (DHFR) inhibitor widely used as an anticancer drug in different kinds of human cancers. Here we investigated the anti-tumor mechanism of MTX against non-small cell lung cancer (NSCLC) A549 cells. MTX not only inhibited in vitro cell growth via induction of apoptosis, but also inhibited tumor formation in animal xenograft model. RNase protection assay (RPA) and RT-PCR demonstrated its induction of p53 target genes including DR5, p21, Puma and Noxa. Moreover, MTX promoted p53 phosphorylation at Ser15 and acetylaion at Lys373/382, which increase its stability and expression. The apoptosis and inhibition of cell viability induced by MTX were dependent on p53 and, partially, on p21. In addition, MTX also increased E-cadherin expression through inhibition of histone deacetylase (HDAC) activity and downregulation of polycomb group protein enhancer of zeste homologue 2 (EZH2). Therefore, the anticancer mechanism of MTX acts through initiation of p53-dependent apoptosis and restoration of E-cadherin expression by downregulation of HDAC/EZH2.
Insights
Methotrexate (MTX) effectively combats non-small cell lung cancer (NSCLC) by triggering programmed cell death (apoptosis) and restoring E-cadherin expression. This anticancer action is mediated through p53 activation and inhibition of HDAC/EZH2 pathways.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Methotrexate (MTX) is a dihydrofolate reductase (DHFR) inhibitor utilized in cancer chemotherapy.
- Non-small cell lung cancer (NSCLC) remains a significant global health challenge.
- Understanding the precise molecular mechanisms of MTX in NSCLC is crucial for optimizing treatment strategies.
Purpose of the Study:
- To elucidate the anti-tumor mechanisms of Methotrexate (MTX) in non-small cell lung cancer (NSCLC) A549 cells.
- To investigate the role of p53 and E-cadherin in MTX-induced anti-cancer effects.
- To explore the impact of MTX on epigenetic regulators like HDAC and EZH2.
Main Methods:
- In vitro cell growth inhibition assays and apoptosis induction studies.
- Animal xenograft models to assess in vivo tumor formation.
- RNase protection assay (RPA) and RT-PCR to analyze gene expression.
- Western blotting to evaluate protein phosphorylation and acetylation.
Main Results:
- MTX inhibited NSCLC A549 cell growth and tumor formation in vivo.
- MTX induced apoptosis via upregulation of p53 target genes (DR5, p21, Puma, Noxa).
- MTX promoted p53 stability and expression through phosphorylation and acetylation.
- MTX increased E-cadherin expression by inhibiting HDAC activity and downregulating EZH2.
Conclusions:
- MTX exhibits anti-cancer effects in NSCLC through p53-dependent apoptosis induction.
- MTX restores E-cadherin expression by modulating HDAC/EZH2 pathways.
- The findings provide insights into MTX's therapeutic potential and mechanisms in NSCLC treatment.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
06:07Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
Related Concept Videos
Abnormal Proliferation
The Intrinsic Apoptotic Pathway
Apoptosis
The Extrinsic Apoptotic Pathway
Mitogens and the Cell Cycle
Drugs that Stabilize Microtubules